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Title: Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility 
Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome  
Abstract:  
Background & Aims: Individuals with hypermobility spectrum disorder or hypermobile Ehlers-Danlos 
Syndrome (HSD/hEDS) are increasingly encountered by gastroenterologists and pose complex clinical 
challenges. Uncontrolled studies have found functional gastrointestinal disorders (FGIDs) to be common in 
patients with HSD/hEDS. Some patients have somatic symptoms (medically unexplained symptoms) that might 
affect FGIDs. We performed a case–control study to determine the prevalence of and factors associated with 
Rome IV FGIDs in subjects with HSD/hEDS compared with age- and sex- matched population-based controls. 
 
Methods:An online general health survey was completed by 603 individuals with HSD/hEDS in October 2018 
(cases) and 603 matched individuals from the population of the United Kingdom (controls) in 2015. The mean 
participant age was 39 yrs, and 96% were women. The survey included questions about Rome IV FGIDs, non-GI 
and non-musculoskeletal somatic symptoms (maximum number, 10), quality of life, medical history and 
healthcare use. The prevalence of FGIDs was compared between cases and controls, with subsequent logistic 
regression models - adjusting for the number of somatic symptoms - used to determine the associations for 
FGIDs in HSD/hEDS compared with controls. 
 
Results: Nearly all subjects (98%) with HSD/hEDS fulfilled symptom-based criteria for 1 or more Rome IV 
FGIDs, compared with 47% of controls (P<.0001). The gastrointestinal regions most commonly affected by 
FGIDs in individuals with HSD/hEDS and control subjects were the bowel (90% vs 40% of controls), 
gastroduodenal (70% vs 13% of controls), esophageal (56% vs 6% of controls), and anorectal (53% vs 9% of 
controls); P<.0001. A higher proportion of subjects with HSD/hEDS had FGIDs in 2 or more regions (84% vs 15% 
of controls; P<.0001). Subjects with HSD/hEDS also reported a significantly higher number of non-GI and non-
musculoskeletal somatic symptoms (7.1 vs 3.3 in controls), lower quality of life, and greater healthcare use, 
including abdominal surgeries and medication use (for example, 84% used analgesics compared with 29% of 
controls). Almost 40% of subjects with HSD/hEDS reported a diagnosis of chronic fatigue syndrome and/or 
fibromyalgia. Following adjustments for somatic symptoms, the association for FGIDs in subjects with 
HSD/hEDS was reduced by as much as 4-fold and in some instances was eliminated. 
 
Conclusions: In a large case–control study of persons with HSD/hEDS, almost all of the cases met criteria for 
Rome IV FGIDs, incurred considerable health impairment, and had high healthcare use. Patients with 
HSD/hEDS frequently have somatic symptoms that should be treated to reduce the high burden of 
gastrointestinal illness in this population. 
 




WHAT YOU NEED TO KNOW 
 
Background: Individuals with hypermobility spectrum disorder or hypermobile Ehlers-Danlos Syndrome 
(HSD/hEDS) are increasingly encountered by gastroenterologists. Little is known about the prevalence of and 
factors associated with functional gastrointestinal disorders (FGIDs) in patients with HSD/hEDS. 
 
Findings: In a large case–control study of persons with HSD/hEDS, almost all of the subjects met criteria for 
Rome IV FGIDs, incurred considerable health impairment, and had high healthcare use.  
 
Implications for patient care: Healthcare providers should aim to control somatic symptoms in patients with 






















Generalised joint hypermobility affects 10-20% of the population and is characterised by the ability to actively 
or passively move joints beyond normal limits.1 The vast majority with joint hypermobility are asymptomatic 
and in these it is considered a benign, harmless trait. Indirect evidence suggests that around 3% of the 
population have hypermobility spectrum disorders (HSD), previously known as joint hypermobility syndrome, 
defined as musculoskeletal symptoms in a hypermobile individual in the absence of systemic rheumatological 
disease.1 However, HSD may be blurred with hypermobile Ehlers-Danlos Syndrome (hEDS), a rare systemic 
connective tissue disorder affecting approximately 1-in-5000 people, due to their overlapping criteria being 
implemented outside specialised centres and the absence of an objective diagnostic biomarker. As such, many 
patient- and research- support groups use the terms HSD and hEDS interchangeably, which will also be the 
case in this article.  
 
Whereas HSD/hEDS has traditionally been confined to rheumatology and pain clinics, the last decade has seen 
emerging data to suggest that individuals with HSD/hEDS are increasingly being encountered within 
gastroenterology services.2-7 Some tertiary-care neurogastroenterology centres report that almost half of their 
new out-patient referrals are accounted for by HSD/hEDS, although arguably this may be an overestimation 
due to referral bias and/or the complex diagnostic criteria being applied by non-rheumatologists.2,3 
Nevertheless, these patients pose substantial therapeutic challenges to healthcare providers given the array of 
highly burdensome intestinal and extra-intestinal symptoms, of which chronic pain is often at the core of the 
most intrusive and debilitating clinical manifestations.2 The majority of HSD/hEDS patients who present with 
gastrointestinal symptoms do not have organic pathology and are diagnosed as having a functional 
gastrointestinal disorder (FGID).2-6 Indeed, studies report that FGIDs can be present in over 90% of subjects 
with HSD/hEDS, although such findings are limited to case-series, cohort studies, and a few small secondary-
care case-control studies.2-12 Moreover, the association between HSD/hEDS and FGIDs may be confounded by 
alternate factors, such as somatic symptoms which -defined as the tendency to report medically unexplained 
symptoms- have been documented in approximately 60% of HSD/hEDS subjects,2 and are of importance for 
symptom severity in FGIDs.13 To date, the prevalence and associations for FGIDs in subjects with HSD/hEDS has 
not been explored against a suitably matched population-based control group. Such an evaluation will help 
clarify the magnitude of gastrointestinal illness in HSD/hEDS and provide insight into identifying potentially 
modifiable risk factors to help alleviate the high symptom burden. It will also aid towards directing future 
clinical service and research provision in this patient group. 
We performed a large case-control study addressing the prevalence and associations for Rome IV FGIDs in 
subjects with HSD/hEDS against age- and sex-matched general population-based controls. We hypothesised 





Materials and Methods 
Study design and participants 
In October 2018, an online general health questionnaire from our research group was sent out by the charity 
organisation Ehlers-Danlos Support UK to its 3874 contactable members. Following an e-mail reminder at two 
weeks, the survey was closed at one month. In total, 777 subjects completed the survey, giving a response rate 
of 20%. All subjects declared a medical diagnosis of Ehlers-Danlos Syndrome. However, the society allows its 
members to use the terms hEDS and HSD interchangeably; therefore, any subject with a supposed diagnosis of 
hEDS was re-classified as HSD/hEDS. Following exclusion of 161 cases for various reasons (82 inconsistent 
responders, 30 with subtypes other than HSD/hEDS, and 49 with co-existing organic gastrointestinal 
pathology; 28 coeliac disease, 22 inflammatory bowel disease, 2 gastrointestinal cancers) there were 616 
subjects with HSD/hEDS who were eligible as the case group.  
Our controls were selected from a nationally representative sample of 1994 population-based UK adults who 
had completed essentially the same survey in 2015, which at that time was used to determine the prevalence 
of FGIDs within the general population.14 From this sample, 54 were excluded due to having an organic 
gastrointestinal pathology; 9 coeliac disease, 25 inflammatory bowel disease and 21 gastrointestinal cancers. 
This left 1940 population-based subjects who were eligible as the control group. 
Following computer generated case-control matching for gender and age (+/- 2 years), the final dataset 
included 603 HSD/hEDS cases and 603 population-based controls; all were matched exactly for gender, with 
91% (n=548) being of the same age and 9% (n=55) within 2 years.  
Questionnaire 
The comprehensive questionnaire collected information on a) basic demographics, b) medical and surgical 
history, c) PHQ-12 somatisation score, which was further condensed to evaluate only non-intestinal/non-
musculoskeletal somatic symptoms (maximum number=10), d) short-form 8 quality of life (SF8-QOL) and e) 
the Rome IV diagnostic questionnaire for the presence of FGIDs. We also analysed a question stem from the 
Rome IV diagnostic questionnaire specifically asking about the frequency of abdominal pain over the last 3 
months. Detailed information on the questionnaires is provided in supplementary material 1.  
Statistical analysis  
Statistical analysis was carried out using SPSS version 25.0 software, with significance set at a p-value of <0.05. 
There was no missing data because the online questionnaire required participants to complete each applicable 
question before being allowed to move onto the next step. Categorical variables were summarized by 
descriptive statistics, including total numbers and percentages, with comparisons between groups performed 
using the chi-square test. Continuous variables were summarized by mean and standard deviation, with 
difference between two independent groups performed using the unpaired student T-test.  
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We then performed binary logistic regression to establish the strength of associations for FGIDS and surgical 
interventions in subjects with HSD/hEDS compared to population controls. This was initially performed 
unadjusted and then adjusted for the number of non-GI/non-musculoskeletal somatic symptoms, as we 




The mean-age of the HSD/hEDS cases and the matched population controls was 39 years (SD=13), with the 
majority aged between 18-34 years (41%) and 35-49 years (36%). Almost all were female (96%) and over 90% 
were white. 
Prevalence of Rome IV FGIDs 
Nearly all subjects (98%, n=591/603) with HSD/hEDS fulfilled symptom-based criteria for one or more Rome IV 
FGIDs compared with 47% (n=285/603) of the population controls; p<0.0001. As listed in table 1, the parts of 
the digestive tract most commonly affected by FGIDs in HSD/hEDS and control subjects were the bowel (90% 
vs. 40%, respectively), gastroduodenal (70% vs. 13%), oesophageal (56% vs. 6%), and anorectal (53% vs. 9%) 
regions; all p<0.0001. Further, 84% of subjects with HSD/hEDS subjects had a FGID in two or more organ 
regions, whereas this occurred in 15% of the population controls; figure 1. The average number of afflicted 
FGID regions in HSD/hEDS was 2.7 versus 0.7 in population controls, p<0.0001. 
 
With regards to individual FGID entities in HSD/hEDS and population controls, the most notable were 
functional dyspepsia (57% vs. 9%), irritable bowel syndrome (54% vs. 8%), functional dysphagia (42% vs. 4%), 
rumination (31% vs. 5%), proctalgia fugax (29% vs. 6%), functional heartburn (24.5% vs. 2%), faecal 
incontinence (16% vs.2%) chronic nausea and vomiting syndrome (14% vs. 1%), and opioid induced 
constipation (10% vs.3%); all p-value<0.0001.  
 
Frequency of abdominal pain 
Over the past 3 months, subjects with HSD/hEDS were significantly more likely than population controls to 
experience abdominal pain at least 1 day per week (75% vs. 14%,p<0.0001); figure 2. Most notably, subjects 
with HSD reported having abdominal pain 2-3 days per week (17.8% vs. 4.4% in controls), most days (23.1% vs. 
2%), everyday (9.5% vs. 0.8%) and multiple times per day (17.6% vs. 0.9%). 
Non-GI/non-musculoskeletal somatic symptoms and quality of life scores 
Compared with population controls, subjects with HSD/hEDS reported a significantly higher PHQ-12 
somatisation score (14.2 vs. 5.6 in controls), with over 95% being categorised as having medium (30% vs. 
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23.5%) to high (66% vs. 5.5%) somatisation severity. The number of non-GI/non-musculoskeletal somatic 
symptoms was also greater in HSD/hEDS compared with population controls (7.1 vs. 3.3, p<0.0001). The 
prevalence of individual somatic symptoms over the preceding four weeks are shown in figure 3, 
demonstrating that subjects with HSD/hEDS were significantly more likely than population controls to report 
bothersome symptoms of headache (85% vs. 58%), chest pain (60% vs. 15%), dizziness (86% vs. 24%), fainting 
spells (29% vs. 5%), palpitations (82% vs. 24%), breathlessness (70% vs. 26%), lethargy (99% vs. 66%), insomnia 
(93% vs. 57%), dyspareunia (51% vs. 8%), and menstrual cramps (52% vs. 45%); all p<0.0001. Subjects with 
HSD/hEDS recorded significantly lower (abnormal) scores across all physical and mental QOL domains; table 1. 
Medical history and Healthcare utilisation 
Subjects with HSD/hEDS were significantly more likely than population controls to have sought 
gastrointestinal-related consultations, in particular with their general practitioner (79% vs. 24%) and a 
gastroenterologist (53% vs. 7%). Approximately 20% of HSD/hEDS subjects had seen a surgeon or a 
gynaecologist, compared with ~1.5% of the population controls. 
A significantly greater prevalence of doctor-diagnosed irritable bowel syndrome (57% vs. 16%) and 
reflux/dyspepsia (46% vs. 12%) was reported in HSD/hEDS compared with population controls. In addition, 
40% of subjects with HSD/hEDS reported a doctor-diagnosis of fibromyalgia and 38% reported chronic fatigue 
syndrome.  
Finally, subjects with HSD/HEDS reported significantly greater use of medication and alternative medicine 
supplements compared with population controls; table 1. This included the use of GI-specific medications (e.g. 
antacids, laxatives), analgesics (84% vs. 29%), and neuromodulators (41% vs. 20%). 
They were significantly greater rates of abdominal surgery in HSD/hEDS, in terms of cholecyestectomy (11% vs. 
3.5%), appendectomy (12% vs. 7%) and hysterectomy (9% vs. 5%), with a trend towards increased bowel 
resection (2% vs. 1%). Subjects with HSD/hEDS had one (19% vs. 12%) or more (7% vs. 2%) of the 
aforementioned abdominal operations, compared with controls; p<0.0001. 
Comparing disease burden in HSD/hEDS subjects vs. the general population who have FGIDs 
Following sub-group analysis, HSD/hEDS subjects with FGIDs (n=591) also demonstrated far greater illness 
burden than their general population counterparts who exhibited FGIDs (n=285); table 2. This was reflected in 
healthcare utilisation, quality of life, somatic symptoms, and FGIDs – where the mean number of afflicted FGID 
regions was 2.8 vs. 1.4, p<0.0001. 
Strength of associations 
The unadjusted odds ratio (UOR) for the presence of FGIDs and surgical interventions in subjects with 
HSD/hEDS compared with population controls are shown in table 3. In particular, these reveal strong 
associations for functional esophageal (UOR 19), gastroduodenal (UOR 16), bowel (UOR 13) and anorectal 
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disorders (UOR 12). Similar associations were seen for the individual FGID clinical entities, including those 
considered as painful FGIDS (e.g. functional chest pain, irritable bowel syndrome, dyspepsia) and non-painful 
FGIDS (e.g. belching, rumination, chronic nausea and vomiting). With regards to abdominal surgery, there was 
a significant association for cholecystectomy (UOR 3.6), appendectomy (UOR 1.7) and hysterectomy (UOR 1.8). 
Following adjustments for amount of non-GI/non-musculoskeletal somatic symptoms, the associations for 
FGIDs in HSD/hEDS was drastically reduced by almost four-fold and in some instances was eliminated. This was 
seen for the painful and non-painful FGIDS. The associations for abdominal surgical interventions became 
largely non-significant. 
Discussion 
To our knowledge this is the first case-control study evaluating the prevalence and associations for Rome IV 
FGIDs in subjects with HSD/hEDS against age- and sex-matched general population-based controls. It shows 
that, in the sampled cohort, nearly all subjects with HSD/hEDS fulfil criteria for a FGID, and that individuals 
with this syndrome incur a considerable amount of somatic symptoms, health-related impairment and health 
care utilisation. These associations are drastically reduced when controlling for somatic symptoms, suggesting 
that they are a relevant confounder towards gastrointestinal illness behaviour in this patient group. 
Our findings corroborate with the published literature regarding the high prevalence of FGIDs in HSD/hEDS, 
although previous studies have been limited to case-series, cohort studies, and small secondary care case-
control studies.2-12 Notably, two national cohort studies, comprising 134 EDS societal members from France 
and over 1000 EDS societal members in the United States, reported that 84% and 93% qualified for at least one 
FGID based on the Rome III criteria, respectively.11,12 Our study substantially adds to the literature due to its 
large sample size, national dissemination, case-control design, exclusion of subjects with organic 
gastrointestinal pathology, evaluation of health impairment and healthcare utilisation, and the use of the 
newly validated Rome IV diagnostic criteria. Importantly, we also evaluated a myriad of somatic symptoms but 
without musculoskeletal symptom reporting, as the latter are directly related to HSD/hEDS and their inclusion 
in analyses of data from these individuals may inflate somatisation scores due to likely organic joint pathology 
involved; previous studies have not controlled for this issue.8 Moreover, we provide data on the number of 
somatic sites involved, not just an overall somatisation severity score, as arguably this provides a clinically 
more relevant picture of disease phenotype.  
The study has potential limitations. For example, it is uncertain whether our findings in HSD/hEDS societal 
members can be generalised to the wider HSD/hEDS community. However, we feel it will represent a vast 
majority, particularly those seeking gastrointestinal consultations, given the similarities in severe illness-
burden shared by HSD/hEDS societal members and those attending clinical practise; data to suggest this is 
appropriately referenced and discussed in greater depth within supplementary material 2. In addition, issues 
pertaining to diagnostic clarity/nomenclature, as well as controversial factors speculated to contribute to 
FGIDs in HSD/hEDS but not studied in our dataset (e.g. connective tissue abnormalities, gut dysmotility, 
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autonomic dysfunction, and mast cell activation disorder) are also discussed in supplementary material 2, with 
their role largely refuted due to a current lack of evidence base. 
Our study raises a number of clinically important points that warrant elaboration, particularly given that 
neurogastroenterology clinics are increasingly being referred or diagnosing patients with HSD/hEDS.2,3 Nearly 
all subjects with HSD/hEDS fulfil criteria for a Rome IV FGID, with the majority having multiple affected FGID 
regions. A recent study has shown that accumulating FGIDs correlates with increasing health impairment and 
healthcare utilisation,13 which typifies the illness pattern seen in HSD/hEDS cohort to a far greater extent than 
their general population counterparts who have FGIDs. To treat the highly burdensome intestinal and extra-
intestinal health-related illnesses of HSD/hEDS would require dedicated clinical time and a multidisciplinary 
team approach, with our study suggesting a strong emphasis be placed on addressing the tendency to 
experience multiple somatic symptoms as they are a fundamental contributor towards reporting FGIDs and 
undergoing potentially unnecessary gastrointestinal surgical interventions.  
 
In fact, the positive correlation between somatic symptoms and increased abdominal surgical rates is a well 
recognised but problematic issue, likely resulting from inaccurate pre-operative diagnosis or failing to 
appreciate the impact of somatic symptoms.13 Previous studies have found that two-thirds of patients with 
HSD/hEDS do not reap benefit following an appendectomy suggesting that symptom reporting was due to 
somatisation as opposed to appendicitis.15 Our dataset shows high surgical rates in HSD/hEDS, including 
almost 1-in-10 cases having undergone a hysterectomy, which could be considered a radical measure given 
that the patient cohort largely comprises women of a fertile age and previous studies have found that visceral 
hypersensitivity frequently drives pelvic pain in subjects with FGIDs.16 Unfortunately, when subjects with 
somatic symptoms undergo such surgical interventions the resected specimen is generally normal and patients 
do not report clinical improvement.17 
 
Hence, familiarity with somatic symptoms in HSD/hEDS and an alternate approach to treat them is required. 
This may be best achieved through targeting central sensitisation, a likely putative pathophysiological factor 
given the multitude of somatic symptoms that are commonly in play alongside the FGIDs and other medically 
unexplained symptoms (e.g. chronic fatigue syndrome and fibromyalgia). This assumption is in line with 
findings of elevated central sensitisation inventory scores in HSD/hEDS, which correlate positively with 
functional disability.18 The notion of addressing centrally-mediated mechanisms in HSD/hEDS is further 
supported by studies showing that psychological distress is a confounder frequently seen in this patient cohort 
and largely underpins gastrointestinal illness behaviour.19 Whilst specific markers of psychological distress 
were not studied in our dataset, elsewhere a recent retrospective study found that almost half of patients with 
HSD/hEDS have a clinical psychiatric disorder, which was significantly associated with somatic muscular pain, 
nerve-related pain and gastrointestinal dysfunction.20 Moreover, triggering of central sensitisation within the 
dorsal horns, via persistent nociceptive input from joint abnormalities, is the postulated mechanism behind 
chronic non-cancer pain in HSD/hEDS.21 Thus, in view of the data largely implicating psychosomatic disorders 
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and central sensitisation as being strongly associated with FGIDs in HSD/hEDS, one would advocate that a 
fundamental aspect of their care encompasses behavioural and pharmacological psychotherapy.22,23 
Randomised controlled trials in FGIDs -including subjects with concurrent somatisation- have shown that 
psychological therapies can lead to an improvement in overall symptoms, with postulated mechanisms being 
through central desensitisation, reduction in hypersensitivity, increase in brain-derived neurotropic factor, and 
an improvement in mood.22,23 Similar studies are needed in HSD/hEDS. 
 
Finally, it is worth highlighting the alarmingly high prevalence of pain medication use in HSD/hEDS, which is in 
line with global epidemic of opioid use and abuse.24 Although our study did not specifically ask about opioid 
use, we did note that over 80% of subjects with HSD/hEDS were taking analgesics. A recent large retrospective 
evaluation of prescription medication use amongst adults with EDS noted the vast majority to be taking 
analgesics, of which opioids accounted for almost two-thirds.25 On this basis, the likely assumption is that 
opioids are the most commonly consumed analgesic in our HSD/hEDS cohort, and when we adjusted for this 
within the logistic regression model it reduced the association for FGIDs (data not shown), albeit to a lesser 
degree than somatic symptoms, suggesting that they are also key players towards ill-health and should be 
weaned. This would fit with ample evidence linking opioids to compounding and deleterious gastrointestinal-
related adverse effects, collectively known as opioid–induced bowel dysfunction.26 Among the most common 
symptoms of opioid-induced bowel dysfunction are abdominal pain, nausea, reflux, vomiting, and 
constipation; what can become extremely troublesome for patients and healthcare providers alike is the 
development of narcotic bowel syndrome, an opioid induced paradoxical hyperalgesia.26 Opioids are also 
associated with substantial systemic harm such as worsening psychopathology, addiction, tolerance, and 
premature death.24 This is of great concern in HSD/hEDS where rapid dose escalation of opioids, alongside the 
co-prescription of sedative drugs such as benzodiazepines, is commonly seen.25 Therefore, extreme caution 
must be advised when prescribing opioids for chronic non-cancer pain conditions, like HSD/hEDS, as the risks 
are substantial yet the evidence to show benefit is lacking.24  
 
In conclusion, this large case-control study shows that HSD/hEDS societal members report a very high 
prevalence of symptoms compatible with Rome IV FGIDs and incur considerable health impairment and health 
care utilisation. These gastrointestinal associations of the syndrome are drastically reduced, and in some 

















Female 580 (96%) 580 (96%) 1.0 
Age 39 (13) 39 (13) 1.0 
Age category 
18 to 34 years 
35 to 49 years 















White race 488/535 (91%) 566 (94%) 0.1 
Single relationship status 264 (44%)) 260 (43%) 0.86 
Symptom Scores 
Somatic Symptom Reporting 







PHQ-12 severity category 
Mild (PHQ ≤3) 
Low (PHQ 4-7) 
Medium (PHQ 8-12) 














Number of non-GI somatic symptoms (max =12) 








    
Short-Form 8 quality of life    
Physical Functioning 48.2 (8.5) 33.3 (8.3) <0.0001 
Role Physical 48.5 (8.9) 31.2 (8.3) <0.0001 
Bodily Pain 50.6 (9.5) 34.7 (6.6) <0.0001 
General Health 45.6 (7.8) 35.2 (7.0) <0.0001 
Vitality 46.9 (8.7) 38.5 (6.5) <0.0001 
Social Functioning 47.8 (9.5) 34.9 (8.6) <0.0001 
Role Emotional 47.1 (7.8) 40.2 (9.5) <0.0001 
Mental Health 46.4 (10.7) 38.7 (11.3) <0.0001 
Functional gastrointestinal disorders 
Functional Oesophageal Disorders 38 (6%) 338 (56%) <0.0001 
Functional Chest pain 6 (1%) 78 (13%) <0.0001 
Functional Heartburn 10 (2%) 148 (24.5%) <0.0001 
Globus 3 (0.5%) 11 (1.8%) 0.13 
Functional dysphagia 26 (4%) 253 (42%) <0.0001 
    
Functional Biliary Disorders 2 (0.3%) 7 (1.2%) 0.18 
    
Functional Gastroduodenal Disorders 77 (13%) 423 (70%) <0.0001 
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Functional dyspepsia 54 (9%) 341 (57%) <0.0001 
Postprandial distress syndrome 46 (8%) 299 (50%) <0.0001 
Epigastric pain syndrome 18 (3%) 197 (33%) <0.0001 
Belching 10 (2%) 70 (12%) <0.0001 
Rumination 28 (5%) 187 (31%) <0.0001 
Chronic Nausea and Vomiting Syndrome 6 (1%) 86 (14%) <0.0001 
Cyclical Vomiting Syndrome 7 (1%) 64 (11%) <0.0001 
    
Functional Bowel Disorders 242 (40%) 541 (90%) <0.0001 
Irritable Bowel Syndrome  48 (8%) 326 (54%) <0.0001 
Functional constipation 59 (10%) 75 (12%) 0.14 
Opioid induced constipation 18 (3%) 60 (10%) <0.0001 
Functional diarrhoea 28 (4.6%) 31 (5%) 0.69 
Functional bloating and distension 39 (6.5%) 17 (2.8%) 0.003 
Unspecified functional bowel disorder 57 (9.5%) 60 (10%) 0.77 
    
Centrally Mediated Abdominal Pain Syndrome 0 (0%) 3 (0.5%) 0.25 
    
Functional Anorectal Disorders 53 (9%) 318 (53%) <0.0001 
Faecal incontinence 12 (2%) 99 (16%) <0.0001 
Levator Ani Syndrome 7 (1%) 113 (19%) <0.0001 
Proctalgia Fugax 37 (6%) 175 (29%) <0.0001 
Healthcare utilisation 
Gastrointestinal-related consultations    
Seen General Practitioner 143 (24%) 476 (79%) <0.0001 
Seen Gastroenterologist 42 (7%) 322 (53%) <0.0001 
Seen Gynaecologist 9 (1.5%) 125 (21%) <0.0001 
Seen Surgeon 7 (1.2%) 118 (20%) <0.0001 
    
Medication    
Laxatives 30 (5%) 167 (28%) <0.0001 
Anti-diarhoeals 17 (3%) 47 (8%) <0.0001 
Antiemetic 13 (2%) 147 (24%) <0.0001 
Antacids 102 (17%) 322 (53%) <0.0001 
Antispasmodics 24 (4%) 125 (21%) <0.0001 
Herbal remedies 30 (5%) 144 (24%) <0.0001 
Traditional Chinese Medicine 1 (0.2%) 8 (1.3%) 0.04 
Analgesia 173 (29%) 507 (84%) <0.0001 
Neuromodulators 120 (20%) 249 (41%) <0.0001 
    
Abdominal Surgery    
Cholecystectomy 21 (3.5%) 69 (11%) <0.0001 
Appendectomy 44 (7%) 71 (12%) 0.01 
Hysterectomy 31 (5%) 53 (9%) 0.01 
Bowel resection 5 (1%) 12 (2%) 0.09 
Note: Data are presented as mean (SD) or n (%) 
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Table 2: Characteristics of subjects with HSD/hEDS who have FGIDs (n=591) and those of the 










Female 278 (98%) 569 (96%) 0.35 










Somatic Symptom Reporting 







PHQ-12 severity category 
Mild (PHQ ≤3) 
Low (PHQ 4-7) 
Medium (PHQ 8-12) 














Number of non-GI somatic symptoms (max=12) 








    
Short-Form 8 quality of life    
Physical Functioning 45.7 (9.8) 33.0 (8.2) <0.0001 
Role Physical 45.7 (10.2) 31.0 (8.2) <0.0001 
Bodily Pain 46.5 (9.3) 34.7 (6.5) <0.0001 
General Health 42.8 (8.1) 35.2 (6.9) <0.0001 
Vitality 44.1 (8.6) 38.4 (6.4) <0.0001 
Social Functioning 44.7 (10.5) 34.9 (8.5) <0.0001 
Role Emotional 45.0 (9.1) 40.2 (9.5) <0.0001 
Mental Health 43.2 (11.3) 38.7 (11.3) <0.0001 
Functional gastrointestinal disorders 
Functional Oesophageal Disorders 38 (13%) 338 (57%) <0.0001 
Functional Chest pain 6 (2%) 78 (13%) <0.0001 
Functional Heartburn 10 (3.5%) 148 (25%) <0.0001 
Globus 3 (1%) 11 (2%) 0.37 
Functional dysphagia 26 (9%) 253 (43%) <0.0001 
    
Functional Biliary Disorders 2 (0.7%) 7 (1.2%) 0.4 
    
Functional Gastroduodenal Disorders 77 (27%) 423 (72%) <0.0001 
Functional dyspepsia 54 (19%) 341 (58%) <0.0001 
Postprandial distress syndrome 46 (16%) 299 (51%) <0.0001 
Epigastric pain syndrome 18 (6%) 197 (33%) <0.0001 
Belching 10 (3.5%) 70 (12%) <0.0001 
Rumination 28 (10%) 187 (32%) <0.0001 
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Chronic Nausea and Vomiting Syndrome 6 (2%) 86 (15%) <0.0001 
Cyclical Vomiting Syndrome 7 (2.5%) 64 (11%) <0.0001 
    
Functional Bowel Disorders 242 (85%) 541 (92%) 0.003 
Irritable Bowel Syndrome 48 (17%) 326 (55%) <0.0001 
Functional constipation 59 (21%) 75 (13%) 0.002 
Opioid induced constipation 18 (6%) 60 (10%) 0.06 
Functional diarrhoea 28 (10%) 31 (5%) 0.01 
Functional bloating and distension 39 (14%) 17 (3%) <0.0001 
Unspecified functional bowel disorder 57 (20%) 60 (10%) <0.0001 
    
Centrally Mediated Abdominal Pain Syndrome 0 (0%) 3 (0.5%) 0.31 
    
Functional Anorectal Disorders 53 (19%) 318 (54%) <0.0001 
Faecal incontinence 12 (4%) 99 (17%) <0.0001 
Levator Ani Syndrome 7 (2.5%) 113 (19%) <0.0001 
Proctalgia Fugax 37 (13%) 175 (30%) <0.0001 
Healthcare utilisation 
Gastrointestinal-related consultations    
Seen General Practitioner 107 (38%) 471 (80%) <0.0001 
Seen Gastroenterologist 35 (12%) 321 (54%) <0.0001 
Seen Gynaecologist 9 (3%) 124 (21%) <0.0001 
Seen Surgeon 7 (2.5%) 117 (20%) <0.0001 
    
Medication    
Laxatives 28 (10%) 167 (28%) <0.0001 
Anti-diarhoeals 15 (5%) 47 (8%) 0.15 
Antiemetic 12 (4%) 146 (25%) <0.0001 
Antacids 68 (24%) 320 (54%) <0.0001 
Antispasmodics 19 (7%) 125 (21%) <0.0001 
Herbal remedies 19 (7%) 139 (24%) <0.0001 
Traditional Chinese Medicine 1 (0.4%) 8 (1.4%) 0.17 
Analgesia 119 (42%) 499 (84%) <0.0001 
Neuromodulators 82 (29%) 245 (42%) <0.0001 
    
Abdominal Surgery    
Cholecystectomy 13 (5%) 69 (12%) 0.001 
Appendectomy 25 (9%) 70 (12%) 0.17 
Hysterectomy 24 (8%) 52 (9%) 0.85 
Bowel resection 5 (2%) 12 (2%) 0.8 






Table 3: Odds ratio (OR) for functional gastrointestinal disorders and abdominal surgery  in 
subjects with HSD/HEDS compared to age- and sex- matched general population controls 
 Unadjusted OR Adjusted  OR 
(controlling for number of 
non-GI/non-musculoskeletal 
somatic symptoms) 
Functional Gastrointestinal Disorders   
Functional Oesophageal disorders 19.0 (13.2-27.3) 6.1 (4.0-9.2) 
Functional chest pain 14.8 (6.4-34.2) 7.4 (2.9-19.0) 
Functional heartburn 19.3 (10.1-37.0) 5.5 (2.7-11.3) 
Functional dysphagia 16.0 (10.5-24.5) 4.9 (3.0-8.0) 
   
Functional Gastroduodenal Disorders 16.1 (11.9-21.6) 5.1 (3.6-7.3) 
Functional dyspepsia 13.2 (9.6-18.3) 3.9 (2.7-5.7) 
Postprandial distress syndrome 11.9 (8.5-16.7) 3.6 (2.4-5.3) 
Epigastric pain syndrome 15.8 (9.6-26.0) 3.8 (2.2-6.7) 
Belching 7.8 (4.0-15.3) 2.6 (1.2-5.7) 
Rumination 9.2 (6.1-14.0) 4.1 (2.5.6.8) 
Chronic nausea & vomiting  syndrome 16.6 (7.2-38.2) 4.2 (1.7-10.5) 
Cyclic vomiting syndrome 10.1 (4.6-22.3) 2.3 (0.95-5.6) 
   
Functional Bowel Disorder 13.0 (9.6-17.7) 4.3 (3.0-6.3) 
Irritable bowel syndrome  13.6 (9.7-19.0) 4.6 (3.1-6.9) 
Opioid induced constipation 3.6 (2.1-6.2) 1.6 (0.8-3.2) 
   
Functional Anorectal disorders 11.6 (8.4-16.0) 4.6 (3.1-6.8) 
Faecal incontinence 9.7 (5.3-17.8) 3.7 (1.8-7.6) 
Levator Ani syndrome 19.6 (9.1-42.5) 7.9 (3.4-18.4) 
Proctalgia fugax 6.3 (4.3-9.1) 3.0 (1.9-4.7) 
Abdominal Surgery   
Cholecystectomy 3.6 (2.2-5.9) 2.8 (1.5-5.5) 
Appendectomy 1.7 (1.1-2.5) 1.5 (0.86-2.5) 











Figure 1: Number of regions affected with a functional gastrointestinal disorder (FGID) is subjects with 





Note: 98% of subjects with HSD/hEDS fulfilled symptom based criteria for a Rome IV FGID, with the majority 
(84%) reporting ≥ 2 affected regions. In contrast, 47% of age/sex-matched general population controls have a 



















As denoted by the arrows, subjects with HSD/HEDS were significantly more likely to have abdominal pain at 


















Figure 3: Presence of bothersome non-GI/non-musculoskeletal somatic symptoms over the past four weeks 




Subjects with HSD/hEDS were significantly more likely than population controls to experience bothersome 
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Supplementary Material 1 
Methods section - Questionnaire 
a) Medical history/healthcare utilisation - Subjects were asked whether they had consulted any of the 
following specialists for gastrointestinal symptoms: general practitioner, gastroenterologist, 
gynaecologist, and surgeon. A reported doctor-diagnosis of irritable bowel syndrome and 
reflux/dyspepsia was determined, but data for chronic fatigue syndrome and fibromyalgia was only 
available for the HSD/hEDS group (where a high prevalence has previously been observed).1-3 We also 
enquired whether the following medications were being taken on at least a weekly basis: laxatives, 
anti-diarrheals, antiemetics, antacids, antispasmodics, herbal remedies, traditional Chinese medicine, 
analgesics, and neuromodulators. Finally, they were asked about history of abdominal surgeries, that 
is cholecystectomy, appendectomy, hysterectomy, and bowel resection.  
 
b) Patient health questionnaire (PHQ)-12 non GI somatic scale4,5 - The PHQ-12 is a modified version of 
the widely used PHQ-15 somatisation questionnaire that excludes the three GI symptoms (nausea, 
abdominal pain, altered bowel habit), as these are likely to be directly related to FGIDs. As a result, 
the PHQ-12 only records bothersome non-GI symptoms over the past month. The twelve symptoms 
assessed are back pain, limb pain, headaches, chest pain, dizziness, fainting spells, palpitations, 
breathlessness, menstrual cramps, dyspareunia, insomnia, and lethargy. Subjects were asked to rate 
how much they had been troubled by these 12 symptoms over the last four weeks as 0 (“not 
bothered at all”), 1 (“bothered a little”), or 2 (“bothered a lot”). The PHQ-12 responses can be used to 
calculate a) the number of sites reporting somatic symptoms (ranging from 0 to 12), b) the overall 
somatisation severity score (ranging from 0 to 24), and c) the somatisation severity category (mild, 
PHQ ≤3; low, PHQ 4-7; medium, PHQ 8-12; high, PHQ ≥13). However, given that the PHQ-12 
somatisation scale includes back pain and limb pain, which in HSD/hEDS may arguably be due to an 
organic disease process, we also present data on the number of somatic symptoms having excluded 
these two musculoskeletal symptoms; this provides a maximum number of 10 non-GI/non-
musculoskeletal somatic symptoms. Higher scores represent greater somatisation, which is generally 
considered to reflect a psychological tendency to report and experience a high amount of general 
body symptoms. 
 
c) Short form (SF)-8 Health Survey6 - This validated questionnaire is commonly used in large scale 
epidemiological studies to assess general health related quality of life (QOL) over the past month. The 
8 items enquire about physical functioning, physical role, bodily pain, general health perceptions, 
vitality, social functioning, emotional role, and mental health. The scores are normalised to the 
general population that has a mean score of 50.6 A high score represents better QOL, whereas low 




d) Rome IV diagnostic questionnaire7 – This validated questionnaire is benchmarked as the principal  
diagnostic tool for FGIDs, and used for diagnosing individuals with these disorders for inclusion into 
clinical trials and in epidemiological surveys. For the purpose of this study we report individuals 
meeting criteria for FGIDs and then categorise them into one of the six anatomical GI regions that 
they belong to i.e. esophageal, gastroduodenal, gallbladder, bowel, anorectal, and centrally-mediated 
disorders of GI pain. Finally, we separately analysed a question stem from the Rome IV diagnostic 
questionnaire that specifically asks about the frequency of abdominal pain over the last 3 months, 
with nine answers that range from “never having abdominal pain” to experiencing “abdominal pain 
multiple times per day”.  
 
Supplementary Material 2 
Discussion – Potential limitations, diagnostic accuracy, and generalizability of findings 
There are potential limitations to our study. Firstly, it could be argued that the high prevalence of FGIDs in 
HSD/hEDS may be accounted for by connective tissue abnormalities within the gastrointestinal tract, which 
was not possible to explore in our study. However, to date, neither collagen defects nor associated mutations 
have been found within the GI tract of patients with HSD/hEDS.8 Moreover, any potential association with 
disordered gut motility has shown conflicting results, with data being limited to a few case series or non-
matched case-control studies, and without controlling for common confounders of GI transit (e.g. opiates, 
tricyclic antidepressants).2,9,10 A relationship between autonomic dysfunction and mast cell activation 
syndrome disorders has also been observed in HSD/hEDS and suggested to cause or aggravate some of the 
symptoms reported.11,12 However, these poorly understood concepts are under scrutiny, as a direct 
pathophysiological basis to explain their presence in HSD/hEDS has not yet been established.13 Rather, the 
presence of autonomic dysfunction has been suggested to arise as a secondary epiphenomenon due to a 
combination of confounding factors including somatic hypervigilance, psychological distress, physical de-
conditioning, poor oral intake, and the use of drugs that can affect neuronal function and possess vasoactive 
properties (e.g. opiates).12,13 With regards to mast cell activation syndrome, a recent comprehensive literature 
review questioned its diagnosis being made outside the realms of allergy units and suggested any current 
association with HSD/hEDS as controversial.13  In summary, more robust research and evidence-base for the 
aforementioned potential factors is warranted.  
Secondly, we did not have access to medical records to confirm or refute the declared doctor diagnosis of 
HSD/hEDS, although arguably this can resemble clinical practise whereby a gastroenterologist or surgeon will 
not have the expertise to question or disentangle the presumed underlying rheumatological diagnosis but 
rather be focused on evaluating the troublesome gut symptoms. Indeed, even within specialist rheumatology 
clinics issues with nomenclature have been inherent within the field of hypermobility-related disorders, 
thereby leading to a heterogeneous pool of patients commonly referred to as HSD/hEDS. The reasons for 
diagnostic blurring have historically been attributed to the subjective application of overlapping criteria for 
24 
 
HSD and hEDS, compounded by the absence of an objective biomarker. To overcome these issues, an 
international consortium published updated guidelines in 2017, whereby far more stringent criteria will 
hopefully improve the diagnostic specificity of hEDS and allow clear distinction from HSD.14,15 In fact, 
subsequent application of the change in criteria has found that of almost 300 patients previously diagnosed 
with hEDS none fulfilled the new diagnostic criteria for hEDS; instead they were all re-classified as HSD.16 This 
would suggest that under the new classification criteria our findings are mainly applicable to patients with HSD 
as opposed to the rare hEDS; however, conceivably patients may still present under the umbrella term for 
both and gastroenterologists should strive to obtain diagnostic clarity from rheumatologists. Our study should 
also not be extrapolated to the other EDS subtypes, such as vascular EDS, which have recognised and 
potentially catastrophic gastrointestinal complications.14  
Finally, there are issues of selection bias when conducting surveys, irrespective of where they are performed 
(e.g. population-based, primary or secondary-care, societal groups) or the methodology used to collect data 
(e.g. postal, telephone, or online). Our study sampled a fifth of the online HSD/hEDS society cohort which may 
viewed as not reflective of non-responders or non-societal members. Nevertheless, it is the largest study of 
this nature to date and did capture individuals throughout the UK, as opposed to within the confines of a 
single centre. We also attempted to reduce potential bias by promoting our survey as “general health” and not 
“gastroenterology-related”. In addition, quality assurance measures were built in within the online 
questionnaire system to ensure we had no missing data and could also exclude inconsistent responders, the 
latter by attention check and repeat questions. It must also be borne in mind that the HSD/hEDS societal 
sample comprised of mainly young to middle aged female subjects who were heavily debilitated by 
widespread symptoms; this demographic profile is characteristic of the HSD/hEDS patient case load seen 
within clinical practise,1,2,8,17-24 of which the majority (~60%) cluster into a complex/severe phenotypic group 
comprising highly burdensome intestinal and extra-intestinal complaints.25,26 Hence, although our findings may 
not necessarily be generalizable to the wider HSD/hEDS community, they are likely to represent a substantial 
proportion and of those seeking GI consults. Another issue worth clarifying is the almost 50% prevalence of 
FGIDs seen in the population control group which - at first glance - may be viewed as on the higher side but 
does fit with the literature given that a third of adults across all age groups (spanning from 18 to over 65 years) 
collectively fulfil criteria for any FGID,27 with the highest concentration of afflicted subjects being young to 










1. Fikree A, Aktar R, Grahame R, et al. Functional gastrointestinal disorders are associated with 
the joint hypermobility syndrome in secondary care: a case-control study. 
Neurogastroenterol Motil. 2015;27(4):569-579. 
2. Nelson AD, Mouchli MA, Valentin N, et al. Ehlers Danlos syndrome and gastrointestinal 
manifestations: a 20-year experience at Mayo Clinic. Neurogastroenterol Motil. 
2015;27(11):1657-1666. 
3. Hakim A, De Wandele I, O'Callaghan C, Pocinki A, Rowe P. Chronic fatigue in Ehlers-Danlos 
syndrome-Hypermobile type. Am J Med Genet C Semin Med Genet. 2017;175(1):175-180. 
4. Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic 
Symptom scale as a predictor of symptom severity and consulting behaviour in patients with 
irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther. 
2010;32(6):811-820. 
5. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the 
severity of somatic symptoms. Psychosom Med. 2002;64(2):258-266. 
6. Ware JE, Kosinski M, Dewey JE, Gandek B. How to Score and Interpret Single-Item Health 
Status Measures: A Manual for Users of the SF-8 Health Survey.  Quality Metric Incorporated   
Lincoln RI. In:2001. 
7. Palsson OS, Whitehead WE, van Tilburg MA, et al. Rome IV Diagnostic Questionnaires and 
Tables for Investigators and Clinicians. Gastroenterology. 2016;150(6):1481-1491. 
8. Beckers AB, Keszthelyi D, Fikree A, et al. Gastrointestinal disorders in joint hypermobility 
syndrome/Ehlers-Danlos syndrome hypermobility type: A review for the gastroenterologist. 
Neurogastroenterol Motil. 2017;29(8). 
9. Zarate N, Farmer AD, Grahame R, et al. Unexplained gastrointestinal symptoms and joint 
hypermobility: is connective tissue the missing link? Neurogastroenterol Motil. 
2010;22(3):252-e278. 
10. Fikree A, Aziz Q, Sifrim D. Mechanisms underlying reflux symptoms and dysphagia in patients 
with joint hypermobility syndrome, with and without postural tachycardia syndrome. 
Neurogastroenterol Motil. 2017;29(6). 
11. Hakim A, O'Callaghan C, De Wandele I, Stiles L, Pocinki A, Rowe P. Cardiovascular autonomic 
dysfunction in Ehlers-Danlos syndrome-Hypermobile type. Am J Med Genet C Semin Med 
Genet. 2017;175(1):168-174. 
12. DiBaise JK, Harris LA, Goodman B. Postural Tachycardia Syndrome (POTS) and the GI Tract: A 
Primer for the Gastroenterologist. Am J Gastroenterol. 2018;113(10):1458-1467. 
13. Kohn A, Chang C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), 
Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome 
(MCAS). Clin Rev Allergy Immunol. 2019. 
14. Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-
Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8-26. 
15. Castori M, Tinkle B, Levy H, Grahame R, Malfait F, Hakim A. A framework for the 
classification of joint hypermobility and related conditions. Am J Med Genet C Semin Med 
Genet. 2017;175(1):148-157. 
16. Wasim S, Suddaby JS, Parikh M, et al. Pain and gastrointestinal dysfunction are significant 
associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and 
hypermobility spectrum disorders: a retrospective study. Rheumatol Int. 2019. 
17. Fikree A, Grahame R, Aktar R, et al. A prospective evaluation of undiagnosed joint 
hypermobility syndrome in patients with gastrointestinal symptoms. Clin Gastroenterol 
Hepatol. 2014;12(10):1680-1687.e1682. 
18. Zweig A, Schindler V, Becker AS, van Maren A, Pohl D. Higher prevalence of joint 




19. Fikree A, Chelimsky G, Collins H, Kovacic K, Aziz Q. Gastrointestinal involvement in the 
Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):181-187. 
20. Hakim AJ, Grahame R. Non-musculoskeletal symptoms in joint hypermobility syndrome. 
Indirect evidence for autonomic dysfunction? Rheumatology (Oxford). 2004;43(9):1194-
1195. 
21. Inayet N, Hayat JO, Kaul A, Tome M, Child A, Poullis A. Gastrointestinal Symptoms in Marfan 
Syndrome and Hypermobile Ehlers-Danlos Syndrome. Gastroenterol Res Pract. 
2018;2018:4854701. 
22. Zeitoun JD, Lefèvre JH, de Parades V, et al. Functional digestive symptoms and quality of life 
in patients with Ehlers-Danlos syndromes: results of a national cohort study on 134 patients. 
PLoS One. 2013;8(11):e80321. 
23. Nee J, Kilaru S, Kelley J, et al. Prevalence of Functional GI Diseases and Pelvic Floor 
Symptoms in Marfan Syndrome and Ehlers-Danlos Syndrome: A National Cohort Study. J Clin 
Gastroenterol. 2019. 
24. Botrus G, Baker O, Borrego E, et al. Spectrum of Gastrointestinal Manifestations in Joint 
Hypermobility Syndromes. Am J Med Sci. 2018;355(6):573-580. 
25. Copetti M, Morlino S, Colombi M, Grammatico P, Fontana A, Castori M. Severity classes in 
adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders: a pilot 
study of 105 Italian patients. Rheumatology (Oxford). 2019. 
26. Schubart JR, Schaefer E, Hakim AJ, Francomano CA, Bascom R. Use of Cluster Analysis to 
Delineate Symptom Profiles in Ehlers-Danlos Syndrome Patient Population. J Pain Symptom 
Manage. 2019. 
27. Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The Prevalence and 
Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on 
Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General 
Population Study in Three Countries. Am J Gastroenterol. 2018;113(1):86-96. 
28. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional gastrointestinal 
disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci. 1993;38(9):1569-
1580. 
 
 
